ArticlePLoS pathogens2013
Shigella IpaH0722 E3 ubiquitin ligase effector targets TRAF2 to inhibit PKC-NF-κB activity in invaded epithelial cells.
Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 67 citations in OpenAlex.
- Article
- Bacteria and Allergic Diseases.International journal of molecular sciences · 2024Review
- Exploiting bacterial effector proteins to uncover evolutionarily conserved antiviral host machinery.PLoS pathogens · 2024Article
- Article
- Exploiting Bacterial Effector Proteins to Uncover Evolutionarily Conserved Antiviral Host Machinery.bioRxiv : the preprint server for biology · 2024Article
- Article
- Ubiquitin-Dependent and Independent Proteasomal Degradation in Host-Pathogen Interactions.Molecules (Basel, Switzerland) · 2023Review
- Ubiquitin-targeted bacterial effectors: rule breakers of the ubiquitin system.The EMBO journal · 2023Review
- Article
- The NEL Family of Bacterial E3 Ubiquitin Ligases.International journal of molecular sciences · 2022Review
- The ubiquitin ligation machinery in the defense against bacterial pathogens.EMBO reports · 2021Review
- Bacteria make surgical strikes on host ubiquitin signaling.PLoS pathogens · 2021Review
- Identification and evaluation of novel vaccine candidates against Shigella flexneri through reverse vaccinology approach.Applied microbiology and biotechnology · 2021Article
- Modification of the host ubiquitome by bacterial enzymes.Microbiological research · 2020Review
- Ubiquitination-Mediated Inflammasome Activation during Bacterial Infection.International journal of molecular sciences · 2019Review
- Review
- Revisiting Bacterial Ubiquitin Ligase Effectors: Weapons for Host Exploitation.International journal of molecular sciences · 2018Review
- Ubiquitin, SUMO, and NEDD8: Key Targets of Bacterial Pathogens.Trends in cell biology · 2018Review
- Synthetic bottom-up approach reveals the complex interplay ofProceedings of the National Academy of Sciences of the United States of America · 2018Article
- Bacterial LPX motif-harboring virulence factors constitute a species-spanning family of cell-penetrating effectors.Cellular and molecular life sciences : CMLS · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NF-κB plays a central role in modulating innate immune responses to bacterial infections. Therefore, many bacterial pathogens deploy multiple mechanisms to counteract NF-κB activation. The invasion of and subsequent replication of Shigella within epithelial cells is recognized by various pathogen recognition receptors as pathogen-associated molecular patterns. These receptors trigger innate defense mechanisms via the activation of the NF-κB signaling pathway. Here, we show the inhibition of the NF-κB activation by the delivery of the IpaH E3 ubiquitin ligase family member IpaH0722 using Shigella's type III secretion system. IpaH0722 dampens the acute inflammatory response by preferentially inhibiting the PKC-mediated activation of NF-κB by ubiquitinating TRAF2, a molecule downstream of PKC, and by promoting its proteasome-dependent degradation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.